Analysis of How the Term “Shall” Is Understood and Applied to the EU-HTA Regulation

Journal of Market Access & Health Policy · Published 2026-07-27 · DOI 10.3390/jmahp14030042

Free full text

Authors (6)

Mondher Toumi, Samuel Aballéa, Bruno Fallissard, Claude Dussart, Pascal Auquier, Laurent Boyer

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Toumi, M., Aballéa, S., Fallissard, B., et al. (2026). Analysis of How the Term “Shall” Is Understood and Applied to the EU-HTA Regulation. Journal of Market Access & Health Policy. https://doi.org/10.3390/jmahp14030042

Related articles

• Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada · Journal of Market Access & Health Policy · 2026 · Same journal
• Joint Clinical Assessment in the EU HTA Regulation—Would Drugs Supported by Single-Arm Trials Fit Under Evaluation? · Journal of Market Access & Health Policy · 2026 · Same journal
• Assessment and Appraisal of Drug Innovativeness in Italy: Ultimate Evidence on Key Drivers and Consistency · Journal of Market Access & Health Policy · 2026 · Same journal
• Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development Strategies · Journal of Market Access & Health Policy · 2026 · Same journal
• Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy · Journal of Market Access & Health Policy · 2026 · Same journal
• Primary Care or Primary Problem? Aligning Access Pathways with Patient Needs Across the Care Continuum · Journal of Market Access & Health Policy · 2026 · Same journal
• Comparative Cost Evaluation of Managed Entry Agreement Techniques Using Real-World Data from High-Cost Anticancer Drugs in Thailand · Journal of Market Access & Health Policy · 2026 · Same journal
• Direct Public-Payer Costs of Dialysis Therapies in Greece: A Patient-Level Micro-Costing Study Across Modality and Provider Sector · Journal of Market Access & Health Policy · 2026 · Same journal
• EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making · Journal of Market Access & Health Policy · 2025 · Same journal
• Balancing Costs and Clinical Outcomes: A Cost-Effectiveness Study of PICC Types Across Chinese Healthcare Settings · Journal of Market Access & Health Policy · 2025 · Same journal